share_log

Trenchant Announces Amendment to the Option Agreement and Closing of the First Tranche of Its Initial Investment in GNQ Insilico Inc.

Trenchant Announces Amendment to the Option Agreement and Closing of the First Tranche of Its Initial Investment in GNQ Insilico Inc.

Trenchant宣布修订期权协议并完成对GNQ Insilico Inc.的第一笔初始投资
newsfile ·  01/04 09:00

Vancouver, British Columbia--(Newsfile Corp. - January 4, 2024) - Trenchant Capital Corp. (CSE: TCC) (the "Company") is pleased to announce that it has entered into an amendment agreement (the "Amendment Agreement") to the previously announced option agreement between the Company and GNQ Insilico Inc. ("GNQ") dated November 30, 2023 (the "Original Option Agreement", and, together with the Amendment Agreement, the "Option Agreement"), pursuant to which the Company has closed the first tranche of its initial investment in GNQ (as defined below), such that the Company now holds approximately 5.6% of the total issued and outstanding common shares in the capital of GNQ (the "GNQ Shares").

不列颠哥伦比亚省温哥华--(Newsfile Corp.,2024 年 1 月 4 日)——Trenchant Capital Corp.(CSE:TCC)(”公司“)很高兴地宣布,它已经签订了修正协议(”修正协议“)转到公司与GNQ Insilico Inc. 之间先前宣布的期权协议(”GNQ“) 日期为 2023 年 11 月 30 日(”原创 期权协议“,以及,连同修正协议,”期权协议“),根据该协议,公司已经完成了对GNQ的第一笔初始投资(定义见下文),因此公司现在持有GNQ资本中已发行和流通普通股总额的约5.6%(”GNQ 股票“)。

As announced by the Company in its news release disseminated on December 1, 2023, the Company entered into the Original Option Agreement with GNQ, pursuant to which GNQ granted the Company the right and option (the "Option") to purchase up to 50% of the GNQ Shares during the period (the "Option Period") commencing on November 30, 2023 and ending on the earlier of November 30, 2026 or the date of a specified liquidity event involving GNQ (as set out in the Option Agreement). Pursuant to the Original Option Agreement, the Company agreed to acquire an initial 20% of the post-investment fully-diluted GNQ Shares for consideration consisting of $2,500,000 and the issuance of 7,500,000 common shares in the capital of the Company (the "Trenchant Shares") to GNQ (collectively, the "Initial Investment").

正如公司在2023年12月1日发布的新闻稿中宣布的那样,公司与GNQ签订了原始期权协议,根据该协议,GNQ授予了公司权利和期权(”选项“)在此期间购买高达50%的GNQ股份(”期权期“)从2023年11月30日开始,到2026年11月30日或涉及GNQ的特定流动性事件发生之日(如期权协议所规定)以较早者为准。根据最初的期权协议,公司同意收购投资后全面摊薄后的GNQ股票的初始20%,包括250万美元和发行公司资本中的750万股普通股(”Trenchant 股票“) 到 GNQ(统称为”初始投资“)。

Pursuant to the Amendment Agreement, the timeline for the payment of the consideration comprising the Initial Investment has been amended such that it will be satisfied by way of: (a) the payment in cash by Trenchant to GNQ of $700,000 on December 29, 2023; and (b) the payment in cash by Trenchant to GNQ of $1,800,000 and the issuance by Trenchant to GNQ of 7,500,000 Trenchant Shares on or prior to February 29, 2024.

根据修正协议,对构成初始投资的对价的支付时间表进行了修改,将通过以下方式予以满足:(a)Trenchant于2023年12月29日以现金向GNQ支付70万美元;(b)Trenchant以现金向GNQ支付1800,000美元,以及Trenchant在当天或之前向GNQ发行750万股Trenchant股票 2024 年 2 月 29 日。

Concurrently with the execution of the Amendment Agreement and closing of the first tranche of the Initial Investment, the Company, GNQ, and MNH (as defined herein) entered into a unanimous shareholders' agreement (the "Shareholders' Agreement") to establish, among other things, the rights and obligations arising out of or in connection with the ownership of GNQ Shares and to govern the relationship between the holders thereof. Pursuant to the Shareholders' Agreement, the Company has the right to appoint one (1) director to the GNQ board of directors which will increase to two (2) should the Company exercise the Option to acquire a 50% ownership interest in GNQ.

在执行修订协议和完成第一笔初始投资的同时,公司、GNQ和MNH(定义见此处)签订了一致的股东协议(”股东协议“)除其他外,确立因GNQ股票所有权而产生或与之相关的权利和义务,并管理其持有人之间的关系。根据股东协议,公司有权为GNQ董事会任命一(1)名董事,如果公司行使收购GNQ50%所有权的期权,该董事会将增加到两(2)名。

GNQ

GNQ

GNQ was formed in August 2023 by My Next Health Inc. ("MNH"), a Delaware incorporated healthcare company with a vision to improve the global healthcare sector by deploying a genomics-based AI and quantum platform for clinical trials and point of care solutions. MNH's platform uses proprietary insights on how systems of genes interact with each other as well as with epigenetic factors to drive key metabolic pathways. These insights are based on more than 15,000 case studies conducted over a decade and are now being scaled and commercialized through a platform that will leverage key exponential technologies to revolutionize personalized healthcare. MNH has exclusive and perpetual global rights to the use of certain technology that relates to functional genomics as well as the supporting clinical data, programs, methods, and interpretation know-how and analytics for use in a number of commercial applications. On November 6th, 2023 GNQ signed a Memorandum of Understanding with a Fortune 100 company towards the development of the in silico clinical trials platform. Both parties are currently working towards the execution of a definitive agreement in respect to the proposed business relationship.

GNQ 由 My Next Health Inc. 于 2023 年 8 月成立。(”MNH“),一家在特拉华州注册成立的医疗保健公司,其愿景是通过部署基于基因组学的人工智能和量子平台进行临床试验和护理点解决方案,改善全球医疗保健行业。MNH的平台使用有关基因系统如何相互作用以及与表观遗传因子相互作用的专有见解来推动关键代谢途径。这些见解基于十年来进行的15,000多个案例研究,目前正在通过一个平台进行扩展和商业化,该平台将利用关键指数技术彻底改变个性化医疗保健。MNH拥有使用与功能基因组学相关的某些技术以及用于多种商业应用的支持性临床数据、项目、方法、解释知识和分析的独家和永久的全球权利。在 11 月 6 日第四,2023 年 GNQ 与一家财富 100 强公司签署了谅解备忘录,以开发计算机临床试验平台。双方目前正在努力执行有关拟议业务关系的最终协议。

ON BEHALF OF THE BOARD

代表董事会

TRENCHANT CAPITAL CORP.

TRENCHANT CAPITAL CORP

Per: "Eric Boehnke"

每个: “Eric Boehnke”

Eric Boehnke, CEO

首席执行官埃里克·博恩克

For further information, please contact:

欲了解更多信息,请联系:

Trenchant Capital Corp.
Eric Boehnke, CEO
Phone: (604) 307-4274

Trenchant 资本公司
首席执行官埃里克·博恩克
电话:(604) 307-4274

TRENCHANT CAPITAL CORP.

TRENCHANT CAPITAL CORP

Certain statements in this press release are forward-looking statements, which reflect the expectations of management regarding the Company's completion of the Initial Investment and related transactions. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, statements regarding MNH's and GNQ's business and potential in the industries in which they operate, the Company completing the transactions as described herein or at all, and the obligations to be satisfied under the Option Agreement and Shareholders' Agreement. Such statements are subject to risks and uncertainties that may cause actual results, performance, or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company. The risks include that the business of MNH and GNQ may not be feasible or continue as planned, as well as other risks that are customary to transactions of this nature. Further, inflationary pressures, rising interest rates, the global financial climate and the ongoing conflicts in Ukraine and the Middle East and surrounding regions are some additional factors that are affecting current economic conditions and increasing economic uncertainty, which may impact the operating performance, financial position, and future prospects of the Company, MNH, GNQ, and the transaction as a whole. Collectively, the potential impacts of this economic environment pose risks that are currently indescribable and immeasurable. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

本新闻稿中的某些陈述是前瞻性陈述,反映了管理层对公司完成初始投资和相关交易的预期。前瞻性陈述由不纯历史的陈述组成,包括任何有关未来信念、计划、预期或意图的陈述,包括但不限于有关MNH和GNQ在其经营行业中的业务和潜力、公司按本文所述完成交易或完全按照期权协议和股东协议应履行的义务的陈述。此类陈述存在风险和不确定性,可能导致实际业绩、业绩或发展与声明中包含的结果存在重大差异,包括与公司无法控制的因素相关的风险。风险包括MNH和GNQ的业务可能不可行或无法按计划继续,以及此类性质交易所惯用的其他风险。此外,通货膨胀压力、利率上升、全球金融环境以及乌克兰和中东及周边地区持续的冲突是影响当前经济状况和增加经济不确定性的其他因素,可能会影响公司、MNH、GNQ和整个交易的经营业绩、财务状况和未来前景。总体而言,这种经济环境的潜在影响构成了目前难以描述和无法估量的风险。无法保证前瞻性陈述所预期的任何事件都会发生,也无法保证如果发生的话,公司将从中获得什么好处。除非法律要求,否则公司不打算或义务更新或修改任何前瞻性陈述,无论是由于新信息、未来事件还是其他原因。

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大证券交易所和市场监管机构(该术语在加拿大证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发